Back to Screener

Healthcare

Biotage AB (publ)(BITGF)

Live Price

Offline

$15.01

+0.00% today

Window Change

+0.94%

Window

Jun 23, 2025 โ†’ Jul 21, 2025

Market Cap
$1.20B
Revenue Growth
+10.4%
EPS Growth
+975.8%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 20 bars ยท Jun 23, 2025 โ†’ Jul 21, 2025

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Biotage AB (publ) (BITGF) is a Healthcare stock with a market cap of $1.20B. The stock last traded around $15.01 and up 0.9% across the available one-year price window (Jun 23, 2025 โ†’ Jul 21, 2025). Baseline metrics include revenue growth of +10.4%, EPS growth of +975.8%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +975.8%, free cash flow +26.4% with operating margin 16.9% and ROIC 3.8%. Valuation already assumes a fairly strong business story at P/E 70.3 and price/sales 11.9. Stock Foundry combines BITGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+10.4% vs +7.6% peer median

Operating Margin

Below sector median

+16.9% vs +19.4% peer median

P/E

Above sector median

70.3 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on Apr 21, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +10.4% and EPS at +975.8%, with operating margin around 16.9%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

BITGF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

BITGF Max Drawdown

-0.40%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for BITGF and SPY.

Calendar-year return history is still loading or unavailable.
BI

Company Overview

Biotage AB (publ)

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
70.3
EV/EBITDA
45.1
Price/Sales
11.9
Price/Book
3.0

Growth

Revenue
+10.4%
EPS
+975.8%
Free Cash Flow
+26.4%

Profitability

Gross Margin
62.3%
Operating Margin
16.9%
Net Margin
16.9%
ROE
4.1%
ROIC
3.8%

Balance Sheet

Debt/Equity
0.06
Current Ratio
2.53

Earnings Reports

๐Ÿ“… Last reportedApr 21, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Apr 21, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Feb 19, 26
โ€”
Est 0.12
โ€”
โ€”
Est 54666.9B
โ€”
โ€”
Oct 23, 25
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 6, 25
โ€”
Est โ€”
โ€”
โ€”
Est 394000.0B
โ€”
โ€”
Apr 24, 25
โœ—
0.00
Est 0.02
-77.2%
38458.1B
Est 40692.3B
-5.5%
โ€”
Feb 19, 25
โœ“
0.18
Est 0.14
+23.2%
52380.0B
Est 59493.0B
-12.0%
โ€”
Oct 23, 24
โœ—
0.05
Est 0.07
-16.7%
47227.5B
Est 48879.1B
-3.4%
โ€”
Jul 16, 24
โœ—
0.06
Est 0.06
-7.1%
47683.7B
Est 46427.3B
+2.7%
โ€”
Apr 25, 24
โœ—
0.04
Est 0.05
-23.2%
44256.0B
Est 42979.6B
+3.0%
โ€”
Feb 15, 24
โœ“
0.17
Est 0.08
+104.5%
63601.0B
Est 53475.7B
+18.9%
โ€”
Sep 29, 23
โœ—
0.04
Est 0.06
-22.6%
40759.0B
Est 41600.9B
-2.0%
โ€”
Jun 29, 23
โœ—
0.05
Est 0.07
-38.6%
37695.3B
Est 36393.9B
+3.6%
โ€”
Mar 30, 23
โœ—
0.06
Est 0.07
-5.0%
34685.2B
Est 35837.8B
-3.2%
โ€”
Feb 15, 23
โœ—
1.11
Est 1.40
-20.7%
37495.9B
Est 40344.0B
-7.1%
โ€”
Nov 2, 22
โœ—
0.98
Est 1.06
-7.5%
35788.5B
Est 36189.5B
-1.1%
โ€”
Jul 19, 22
โœ“
0.87
Est 0.84
+3.6%
38395.7B
Est 35390.3B
+8.5%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks